CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Capricor Therapeutics, Inc.

CAPR
$1.64B
Small Cap
NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO160 employees
Website

Drugs in Pipeline

5

Phase 3 Programs

2

Upcoming Catalysts

1

Next Catalyst

Aug 22, 2026

4d

Market Overview

Stock performance and key metrics

CAPR News
Catalyst Timeline

1 upcoming, 1 past

RegulatoryNext

Regulatory — deramiocel

Aug 22, 2026

For Duchenne muscular dystrophy. Capricor Therapeutics' stock surged 68% on CEO commentary suggesting the FDA may extend its review timeline for deramiocel, a Duchenne muscular dystrophy cell therapy, ahead of the August 22 deadline.

Source

How CAPR's past catalysts played out

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Capricor Therapeutics, Inc.'s drug pipeline?

CatalystAlert tracks 5 drug candidates in Capricor Therapeutics, Inc.'s (CAPR) pipeline across Phase 3, Phase 2. Its lead program is CAP-1002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Capricor Therapeutics, Inc.'s next FDA catalyst?

Capricor Therapeutics, Inc.'s (CAPR) next tracked catalyst is a Earnings expected August 17, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track CAPR biotech catalysts?

Add CAPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Capricor Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply